Cosentyx (secukinumab) is a medication used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, its safety during pregnancy is not well-established. The available sources suggest that Cosentyx should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus.
According to DrugPatentWatch [1], Cosentyx is classified as a Pregnancy Category B drug by the US Food and Drug Administration (FDA). This means that animal studies have not shown any adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women. Therefore, Cosentyx should be used during pregnancy only if clearly needed.
A recent review article published in the Journal of Clinical Medicine [2] reported that there is limited data on the use of Cosentyx during pregnancy. However, based on the available evidence, it is recommended that women of childbearing age who are planning to become pregnant should discontinue Cosentyx at least 20 weeks before conception. This is because Cosentyx has a long half-life, and it may take several months for the drug to be eliminated from the body.
Drugs.com [3] also recommends that Cosentyx should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. The website suggests that women who are pregnant or planning to become pregnant should discuss the risks and benefits of Cosentyx with their healthcare provider.
In summary, the available sources suggest that the safety of Cosentyx during pregnancy is not well-established. While animal studies have not shown any adverse effects on the fetus, there are no adequate and well-controlled studies in pregnant women. Therefore, Cosentyx should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus. Women of childbearing age who are planning to become pregnant should discontinue Cosentyx at least 20 weeks before conception. It is recommended that pregnant women or those planning to become pregnant discuss the risks and benefits of Cosentyx with their healthcare provider.
Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/
[3] https://www.drugs.com/pregnancy/secukinumab.html